With vague symptoms and no screening test, ovarian cancer can be deadly. According to NCI’s Surveillance, Epidemiology and End Results program, 20,890 people will receive an ovarian cancer diagnosis in 2025 and of these, more than half will learn that their ovarian cancer has spread to distant organs.
Personalis Inc. announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, which demonstrated the clinical importance of ultrasensitive, tumor-informed molecular residual disease testing in stage 1 to 3 non-small cell lung cancer.
FDA has approved rucaparib (Rubraca) for adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor-directed therapy.
FDA and OS Therapies held a Type C meeting regarding the phase IIb human clinical trial of OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma.
FDA has awarded a National Priority Voucher to teclistamab (Tecvayli) in combination with daratumumab (Darzalex) for relapsed/refractory multiple myeloma. This brings the total number of products receiving an award under the Commissioner’s National Priority Voucher pilot program to 16.
The European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grade 1-3a) after at least one line of systemic therapy.
John C. Byrd grew up in Augusta, a town of 2,000 or so in northeastern Arkansas.
FDA has withdrawn a proposed rule that called for standardized testing for detecting and identifying asbestos in talc-containing cosmetic products.
The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?
Harvey A. Risch, professor emeritus and senior research scientist at Yale School of Public Health, said he was named chair of the President’s Cancer Panel. Risch will succeed Elizabeth M. Jaffee, who was appointed by President Joe Biden in January 2023.
